Evidence map›Paper›PMID 11172068›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2001

Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans.

K Ohno, A Tsujino, J M Brengman, C M Harper, Z Bajzer, B Udd, R Beyring, S Robb, F J Kirkham, A G Engel

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 2 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 263 citations in OpenAlex.

  1. Congenital myasthenic syndromes.Orphanet journal of rare diseases · 2019
    Pooled it
  2. Pooled it
  3. Convergent evidence that choline acetyltransferase gene variation is associated with prospective smoking cessation and nicotine dependence.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010
    Trial
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. The Central Cholinergic Synapse: A Primer.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Article
  13. Mild phenotype ofFrontiers in pediatrics · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

K OhnoDepartment of Neurology and Neuromuscular Research Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
A Tsujino
J M Brengman
C M Harper
Z Bajzer
B Udd
R Beyring
S Robb
F J Kirkham
A G Engel
Guy's Hospital · GBMayo Clinic · US

Funding

ELECTRON MICROSCOPY OF MYOPATHIESR01NS006277 · NINDS · MAYO CLINIC ROCHESTER · PI ENGEL, ANDREW GEORGE · 1985 to 2015
$7.8M
Congenital Myasthenic SyndromesR56NS006277 · NINDS · MAYO CLINIC ROCHESTER · PI ENGEL, ANDREW GEORGE, SELCEN, DUYGU · 2017 to 2017
$539k
NINDS NIH HHS NS6277NINDS NIH HHS R01 NS006277NINDS NIH HHS R56 NS006277
6 · The paper itself

Abstract

Choline acetyltransferase (ChAT; EC ) catalyzes the reversible synthesis of acetylcholine (ACh) from acetyl CoA and choline at cholinergic synapses. Mutations in genes encoding ChAT affecting motility exist in Caenorhabditis elegans and Drosophila, but no CHAT mutations have been observed in humans to date. Here we report that mutations in CHAT cause a congenital myasthenic syndrome associated with frequently fatal episodes of apnea (CMS-EA). Studies of the neuromuscular junction in this disease show a stimulation-dependent decrease of the amplitude of the miniature endplate potential and no deficiency of the ACh receptor. These findings point to a defect in ACh resynthesis or vesicular filling and to CHAT as one of the candidate genes. Direct sequencing of CHAT reveals 10 recessive mutations in five patients with CMS-EA. One mutation (523insCC) is a frameshifting null mutation. Three mutations (I305T, R420C, and E441K) markedly reduce ChAT expression in COS cells. Kinetic studies of nine bacterially expressed ChAT mutants demonstrate that one mutant (E441K) lacks catalytic activity, and eight mutants (L210P, P211A, I305T, R420C, R482G, S498L, V506L, and R560H) have significantly impaired catalytic efficiencies.

Indexed as

MutationAdultAmino Acid SequenceAnimalsApneaBungarotoxinsChildChild, PreschoolChlorocebus aethiopsCholine O-AcetyltransferaseCOS CellsEscherichia coliFemaleHumansKineticsMaleBungarotoxinsCholine O-Acetyltransferase

Identifiers

PMID11172068
PMCPMC29374
OpenAlexW2085130401

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.